sur Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS)
Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement
Palvella Therapeutics and Pieris Pharmaceuticals have entered into a merger agreement to form a Nasdaq-listed biopharmaceutical company. The combined entity will focus on developing treatments for rare genetic skin diseases, including the QTORIN™ 3.9% rapamycin anhydrous gel for microcystic lymphatic malformations.
The merger will equip the new company with around $80.5 million in cash and cash equivalents by the end of 2027, facilitated by a $78.9 million private financing from healthcare investors. This funding is expected to support various clinical trial milestones, including a pivotal Phase 3 trial for QTORIN™ rapamycin under the FDA's Breakthrough and Fast Track Designation programs.
The combined company will operate under the name Palvella Therapeutics, Inc., headquartered in Wayne, PA, and will trade on The Nasdaq Capital Market. The anticipated merger and financing are set to close in the fourth quarter of 2024, pending stockholder approval and regulatory conditions.
R. H.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Pieris Pharmaceuticals, Inc.